Chairs: Simon Williams
Speakers: Dr Devaki Nair, Darren Harvey
In association with HEART UK
PCSK9 inhibitors provide an effective way of lowering LDL cholesterol in high risk patients. This however comes at a cost to the NHS. Accurate information should be obtained from the outset so as to ensure a seamless application process for funding. Rigorous clinical monitoring ensures the safe use of a relatively new drug. Education of lipid clinic staff is essential in ensuring that this process becomes an integral part of the lipid clinic. The development of this service has highlighted various challenges however this had led to increased knowledge of using the drug.